November 25, 2016 - By Dolores Ford · 0 Comments
The stock of Bellicum Pharmaceuticals Incorporated (NASDAQ:BLCM) registered a decrease of 0.69% in short interest. BLCM’s total short interest was 2.96M shares in November as published by FINRA. Its down 0.69% from 2.98M shares, reported previously. With 184,100 shares average volume, it will take short sellers 16 days to cover their BLCM’s short positions. The short interest to Bellicum Pharmaceuticals Incorporated’s float is 14.17%. The stock increased 0.10% or $0.02 during the last trading session, hitting $20.65. About 81,371 shares traded hands. Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) has risen 79.39% since April 22, 2016 and is uptrending. It has outperformed by 73.98% the S&P500.
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $551.71 million. The Firm is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. It currently has negative earnings. The Firm uses its chemical induction of dimerization technology platform to engineer and then control components of the immune system.
Out of 7 analysts covering Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), 5 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 71% are positive. Bellicum Pharmaceuticals Inc has been the topic of 10 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Citigroup maintained Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) on Tuesday, August 9 with “Neutral” rating. The stock has “Hold” rating given by Zacks on Wednesday, August 19. The rating was initiated by Citigroup with “Buy” on Friday, July 24. The stock has “Neutral” rating given by Citigroup on Thursday, February 25. The firm earned “Buy” rating on Friday, June 3 by SunTrust. Zacks downgraded the stock to “Sell” rating in Monday, September 21 report. The rating was upgraded by Guggenheim on Friday, September 11 to “Buy”. On Wednesday, November 2 the stock rating was initiated by Cantor Fitzgerald with “Buy”. The firm earned “Buy” rating on Tuesday, August 9 by Jefferies. As per Friday, June 3, the company rating was initiated by Suntrust Robinson.
Bellicum Pharmaceuticals, Inc., incorporated on July 14, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Firm uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Firm is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. The Company’s CID technologies include CaspaCIDe, CIDeCAR and GoCAR-T.
More notable recent Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) news were published by: Marketwatch.com which released: “Bellicum Pharmaceuticals upgraded to buy from neutral at Citigroup” on December 18, 2014, also Fool.com with their article: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Juno Therapeutics, Inc.” published on June 26, 2016, Fool.com published: “Better Buy: Agenus Inc. vs. Bellicum Pharmaceuticals Inc.” on October 18, 2016. More interesting news about Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) were released by: Fool.com and their article: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Celldex Therapeutics” published on August 03, 2016 as well as Quotes.Wsj.com‘s news article titled: “News Bellicum Pharmaceuticals Inc.BLCM” with publication date: December 13, 2014.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Dolores Ford